Abstract:Multiple preventive COVID-19 vaccines have been developed during the ongoing SARS coronavirus (CoV) 2 pandemic, utilizing a variety of technology platforms, which have different properties, advantages, and disadvantages. The acceleration in vaccine development required to combat the current pandemic is not at the expense of the necessary regulatory requirements, including robust and comprehensive data collection along with clinical product safety and efficacy evaluation. Due to the previous development of vaccine candidates against the related highly pathogenic coronaviruses SARS-CoV and MERS-CoV, the antigen that elicits immune protection is known: the surface spike protein of SARS-CoV-2 or specific domains encoded in that protein, e.g., the receptor binding domain. From a scientific point of view and in accordance with legal frameworks and regulatory practices, for the approval of a clinic trial, the Paul-Ehrlich-Institut requires preclinical testing of vaccine candidates, including general pharmacology and toxicology as well as immunogenicity. For COVID-19 vaccine candidates, based on existing platform technologies with a sufficiently broad data base, pharmacological–toxicological testing in the case of repeated administration, quantifying systemic distribution, and proof of vaccination protection in animal models can be carried out in parallel to phase 1 or 1/2 clinical trials. To reduce the theoretical risk of an increased respiratory illness through infection-enhancing antibodies or as a result of Th2 polarization and altered cytokine profiles of the immune response following vaccination, which are of specific concern for COVID-19 vaccines, appropriate investigative testing is imperative. In general, phase 1 (vaccine safety) and 2 (dose finding, vaccination schedule) clinical trials can be combined, and combined phase 2/3 trials are recommended to determine safety and efficacy. By applying these fundamental requirements not only for the approval and analysis of clinical trials but also for the regulatory evaluation during the assessment of marketing authorization applications, several efficacious and safe COVID-19 vaccines have been licensed in the EU by unprecedentedly fast and flexible procedures. Procedural and regulatory–scientific aspects of the COVID-19 licensing processes are described in this review.

Development of Next-Generation COVID-19 Vaccines: BARDA Supported Phase 2b Study Designs

Project NexGen: Developing the Next Generation of COVID-19 Vaccines and Therapeutics to Respond to the Present and Prepare for the Future

Next-generation COVID-19 Vaccines: Opportunities for Vaccine Development and Challenges in Tackling COVID-19

Status Report on COVID-19 Vaccines Development

Accelerate Vaccine Development Using Seamless Phase 2/3 Trial Designs

Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks

Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

COVID-19 Vaccines: Where Did We Stand at the End of 2023?

Advances in gene-based vaccine platforms to address the COVID-19 pandemic

An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations

An overview of vaccine development for COVID-19

SARS-CoV-2 Vaccine Development: Current Status

Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Challenges and Recent Advancements in COVID-19 Vaccines

Finally neutralizing the threat? A novel SARS-CoV-2 vaccine platform that elicits enhanced neutralizing antibody responses

Microfluidic Synthesis of Scalable Layer-by-Layer Multiple Antigen Nano-Delivery Platform for SARS-CoV-2 Vaccines

A multitope SARS-COV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants

Application of Traditional Vaccine Development Strategies to SARS-CoV-2